Sign up
Pharma Capital
Why invest in PIQ?

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions

Richard Lipscombe talked revenue generation and growth path with investors.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
BigPicture
Richard Lipscombe, MD, Proteomics International Laboratories

Proteomics International Laboratories (ASX:PIQ) managing director, Richard Lipscombe, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.

Proteomics is a revenue generating company holding the unique position as having the world's first diagnostic test at a commercialisation stage.

The company has proven technology with patents granted, with an Asian focus and global reach.

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future PIQ Company articles
View full PIQ profile

Proteomics International Laboratories Timeline

View All

Related Articles

Cattle-herd-(Resized).jpg
If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.